Hospital Reina SofíaMurcia, Spain
RHEUMATOLOGIST
2373: Effectiveness and Tolerability of Guselkumab or TNF inhibitors as Second-Line Treatment After Receiving a TNF inhibitor as First-Line Therapy to Treat Active Psoriatic Arthritis: 52-Week Interim Data from the Manhattan Study
Tuesday, October 28, 202510:30 AM - 12:30 PM Central Time
Disclosure(s): No financial relationships with ineligible companies to disclose
